| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/21/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
AW
| Form AW - Amendment Withdrawal Request: |
| 07/10/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/03/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/01/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2021 [amend] |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/28/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors SIOUX FALLS, S.D., April 4, 2023 -- SAB Biotherapeutics , , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to SAB’s Board of Directors, effective April 4, 2023. Most recently, Mr. Lucera served as chief financial officer for AVEO Oncology, a commercial stage oncology-focused biopharmaceutical company, from January 202..." |
|
| 03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/31/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister... |
| 03/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 02/13/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/09/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/07/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/03/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 02/03/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/27/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
|